Keyphrases
China
100%
Cost-effectiveness
100%
Guangxi
100%
Guangxi Zhuang Autonomous Region
100%
Antiretroviral Therapy
42%
Standard of Care
42%
Incremental Cost-effectiveness Ratio
42%
HIV Testing
28%
Disease Prevention
28%
Centers for Disease Control
28%
Quality-adjusted Life Years
28%
County Hospital
28%
HIV Screening
28%
Disease Progression
14%
Economic Impact
14%
AIDS/HIV
14%
Health Benefits
14%
Health Systems
14%
Health Economics
14%
HIV Disease Progression
14%
Point-of-care
14%
Prevention Strategies
14%
Early Antiretroviral Therapy
14%
Counseling
14%
Cluster Randomized Trial
14%
Testing Strategy
14%
Same-day
14%
HIV Epidemic
14%
HIV Transmission
14%
Sensitivity Analysis
14%
Life-years Gained
14%
Disease-specific Mortality
14%
Mortality Costs
14%
Testing Interventions
14%
HIV Incidence
14%
Viral Load Monitoring
14%
HIV Cases
14%
HIV Transmission Networks
14%
Combination Prevention
14%
WHO Standards
14%
Public Health Response
14%
Subsequent Therapy
14%
Morbidity Mortality
14%
Treatment Uptake
14%
Averted Deaths
14%
HIV Testing Algorithm
14%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Human Immunodeficiency Virus
100%
Gene Linkage
100%
Antiretroviral Therapy
40%
Health Care Cost
30%
HIV Test
30%
Disease
20%
Quality Adjusted Life Year
20%
Health System
10%
HIV/AIDS
10%
Public Health
10%
Disease Exacerbation
10%
Cluster Randomized Trial
10%
Viral Load Testing
10%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
36%
Health Care Quality
27%
HIV Test
27%
Quality Adjusted Life Year
18%
Incremental Cost-Effectiveness Ratio
18%
Disease Control
18%
Prophylaxis
18%
World Health Organization
9%
Public Hospital
9%
Disease Exacerbation
9%
Nutrition Policy
9%
Viral Load Testing
9%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus
100%
Gene Linkage
100%
Quality Adjusted Life Year
14%
Cluster Randomized Trial
7%
Virus Load
7%
CD4
7%
Psychology
Standard of Care
100%
Time Horizon
66%
Public Health
33%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Disease
14%
Cluster Randomized Trial
7%
Disease Exacerbation
7%